Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Agomelatine versus fluoxetine in severe major depressive disorder
2004-004008-19Phase 3Completed
- Sponsor
- Servier
- Start
- Mar 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of agomelatine in major depressive disorder (MDD) (2 arms), sponsored by Servier. Primary endpoint: Agomelatine superiority to fluoxetine on HAM-D17 at 8 weeks. Started Mar 2005; status: completed.
02
Drugs
agomelatine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2004-004008-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004008-19.